Status:
COMPLETED
The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes
Lead Sponsor:
Amsterdam UMC, location VUmc
Conditions:
Diabetes Mellitus, Type 2
Insulin Sensitivity/Resistance
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This study examines the effects of iloprost - a stable prostacyclin analogue - on insulin-mediated muscle capillary recruitment and whole-body glucose uptake in a cross-over design.
Detailed Description
In type 2 diabetes impaired insulin-mediated muscle perfusion is thought to contribute to reduced whole-body glucose uptake. This study aims to identify iloprost - a stable prostacyclin analogue - as ...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Male or female (post-menopausal)
- Age above 45 years and below 70 years
- BMI \>30 kg/m2
- HbA1c \< 80 mmol/mol or \< 8,6% Subjects must use metformin
- Stable medication use
- Stable tension regulation (with or without medication)
- Subjects should be able to give informed consent
Exclusion
- A history of cardiovascular event (Cerebrovascular event, myocardial infarction or pacemaker implantation)
- Severe-very severe lung emphysema (GOLD stage III-IV)
- Use of any antibiotics or proton pump inhibitor (PPI) in the past three months
- Use of any other antidiabetic medication besides metformin (e.g. SU-derivates, insulin)
- Use of a platelet inhibitor or cumarin derivate during
- Subjects participated in a lifestyle programme in the past 6 months (diet or exercise)
Key Trial Info
Start Date :
May 11 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2017
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03380325
Start Date
May 11 2016
End Date
June 29 2017
Last Update
July 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VU University Medical Center
Amsterdam, North Holland, Netherlands, 1081 HV